

Financial Results for the 1st quarter of the year ending March 31, 2021

August 6, 2020



1. Financial Results for the 1st quarter of the year ending March 31, 2021

2. Forecast for the year ending March 31, 2021

Summary for the 1st quarter of the year ending March 31, 2021



Q1 Actual

YoY

• Revenue: ¥64.7B

Operating Profit: -¥20.5B

• Revenue: Down ¥78.2B

Operating profit: Down ¥29.8B

- The impact of COVID-19 is enormous, revenue declined in all segments, then in deficit.
 - Imaging Products: Revenue down ¥42.2B. Profit down ¥11.6B.

 Digital camera sales volumes dropped substantially due to restrictions on movement, suspension of distributors, etc.
 - Precision Equipment: Revenue down ¥32.2B. Profit down ¥15.4B.

 Particularly in FPD lithography business, systems could not resume its installation due to travel restrictions. No sales of system has posted in Q1.

Note: Amounts in this statement are rounded down to the hundred millions of yen.

1st quarter of the year ending March 31, 2021: Financial Highlights



Billions of yen	FY2020/3 Q1 Actual (A)		
Revenue	142.9	64.7	-78.2
Operating Profit % vs Revenue	9.3 6.5%	-20.5 -31.7%	-29.8
Profit before income taxes % vs Revenue	10.7 7.5%	-19.2 -29.7%	-29.9
Profit attributable to owners of the parent % vs Revenue	8.2 5.7%	-13.5 -20.9%	-21.7
FCF	-0.7	-18.2	-17.5
Exchange Rate: US \$ EURO	¥ 110 ¥ 124	¥108 ¥119	Impact on Revenue -1.7 Impact on Operating Profit -0.3

Profit attributable to owners of the parent and FCF deteriorated significantly due to a decline in revenue of more than 50% YoY.

1st quarter of the year ending March 31, 2021: Financial Highlights by Segment



Billions of yen		FY2020/3 Q1 Actual (A)	FY2021/3 Q1 Actual (B)	Change (B)-(A)
Imaging Products	Revenue	67.3	25.1	-63%
Business	Operating profit	3.5	-8.1	-¥11.6B
Precision Equipment	Revenue	51.8	19.6	-62%
Business	Operating profit	10.3	-5.1	-¥15.4B
Hooltheave Business	Revenue	12.9	10.3	-20%
Healthcare Business	Operating profit	-1.9	-2.4	-¥0.5B
Industrial Metrology	Revenue	10.8	9.5	-12%
and Others	Operating profit	0.2	-0.4	-¥0.6B
Corporate P/L non-	Revenue	_	-	-
attributable to any reportable segments	Operating profit	-2.9	-4.4	-¥1.5B
Consolidated	Revenue	142.9	64.7	-55%
Consolidated	Operating profit	9.3	-20.5	-¥29.8B

Corporate P/L non-attributable to any reportable segments improved ¥2.3B, excluding ¥3.8B gain from the sales of unused land booked in the previous fiscal year.

Note: The Semiconductor Related Equipment Business, which had belonged to Industrial Metrology and Others, has been transferred to the Precision Equipment Business. Revenue of ¥0.9B and operating profit of ¥0.2B have been transferred from Industrial Metrology and Others to the Precision Equipment Business as a result of retroactive application to FY2020/3.

1st quarter of the year ending March 31, 2021: Imaging Products Business



Billions of yen	FY2020/3 Q1 Actual (A)	FY2021/3 Q1 Actual (B)	Change (B)-(A)
Revenue	67.3	25.1	-42.2
Operating profit % vs Revenue	3.5 5.2%	-8.1 -32.3%	-11.6
Digital Camera- Interchangeable Lens type (Units sold: 1,000)	450	140	-310
Interchangeable Lens (Units sold: 1,000)	740	220	-520
Compact DSC (Units sold: 1,000)	270	50	-220

Q1 YoY:

- Business activities in China has recovered as previous fiscal year and other regions bottomed out in April and have been on a gradual recovery trend since. Nevertheless, effects including restrictions on movement and suspension of distributors due to lock downs have been immense. Sales volumes dropped substantially in all categories.
- The substantial decline in revenue outweighed efforts to rein in sales expenses, yet, deficit was recorded for the first time in Q1.

1st quarter of the year ending March 31, 2021: Precision Equipment Business



Billions of yen	FY2020/3 Q1 Actual (A)	FY2021/3 Q1 Actual (B)	Change (B)-(A)
Revenue	51.8	19.6	-32.2
Operating profit % vs Revenue	10.3 19.9%	-5.1 -26.0%	-15.4
FPD Lithography Systems (units)	9	0	-9
Semiconductor Lithography Systems New/Refurbished (units)	6/1	2/1	-4/± 0

Q1 YoY:

- In the FPD Lithography Business, the installations that have been halted since February could not be resumed by June. Therefore, no sales of system has been booked.
- In the Semiconductor Lithography Business, sales were booked for the systems which its installation began last year continued into this quarter. Installation of some systems, however, were completed early and booked last year. Therefore, Q1 sales volumes dropped substantially.

1st quarter of the year ending March 31, 2021: Healthcare Business



Billions of yen	FY2020/3 Q1 Actual (A)	FY2021/3 Q1 Actual (B)	Change (B)-(A)
Revenue	12.9	10.3	-2.6
Operating profit % vs Revenue	-1.9 -14.7%	-2.4 -23.3%	-0.5

Q1 YoY:

• Revenue and profit dropped in biological microscopes as well as retinal diagnostic imaging systems due to decreased orders since February as a result of lock downs, etc. Biological microscope sales volumes dropped mainly in the Americas. Retinal diagnostic imaging systems had significant impact by delayed recoveries in core markets of the US and Europe.

1st quarter of the year ending March 31, 2021: Industrial Metrology and Others



Billions of yen	FY2020/3 Q1 Actual (A)	FY2021/3 Q1 Actual (B)	Change (B)-(A)
Revenue	10.8	9.5	-1.3
Operating profit % vs Revenue	0.2	-0.4 -4.2%	-0.6

Q1 YoY:

Revenue and profit dropped mainly in the Industrial Metrology due to the delay in customers investment continued from the end of last year, on top of that, restrictions on sales activities and the postponement of deliveries due to the impact of COVID-19.



1. Financial Results for the 1st quarter of the year ending March 31, 2021

2. Forecast for the year ending March 31, 2021

Forecast for the year ending March 31, 2021



Revenue ¥420.0B

Company total forecast: Revenue down ¥171.0B YoY

- **Imaging Products Business:** Revenue decreased ¥95.8B (-42.4%) by the impact of COVID-19 couple with market shrinkage drove down sales volumes.
- **Precision Equipment Business:** Revenue decreased ¥70.0B (-28.6%) as our main customer is at their shifting point of investment in Semiconductor lithography business couples with installation delays by the impact of COVID-19 in FPD lithography business.

Operating profit -¥75.0B

Company total forecast: Profit down ¥81.7B YoY

- **Imaging Products Business:** Profit decreases ¥22.9B, deficit of ¥40.0B due to market shrinkage and the impact of COVID-19 in spite of reductions to business costs.
- **Precision Equipment Business:** Profit decrease ¥38.0B, profit of ¥10.0B by the Impact of COVID-19 couples with increased development investments in growth areas.
- **Corporate P/L non-attributable to any reportable segments:** ¥20.0B of risk buffer are posted for further performance fluctuation risk.

Financial soundness

- Financial soundness is well secured even with the assumption of -¥50.0B of Profit Attributable to Owners of the Parent.
 - **Equity capital:** Equity capital expected to remain at least 50% or more after the end of the fiscal year
 - **Liquidity on hand:** Secured more than ¥400.0B in total of cash on hand and commitment lines of credit etc. for working capital.

Dividends

• **Dividend forecast:** Based on the policy of total return ratio of 40% or more (cumulative period of Medium-Term Management Plan): annual ¥20. (interim: ¥10)

Management responsibility

• Executive compensation:

Effective in September 2020 for the foreseeable future, reduce monthly pay up to 20% and pay no bonuses in FY2021/3.

Forecast for the year ending March 31, 2021: Financial Highlights




Billions of yen	FY2020/3 Actual (A)	FY2021/3 Forecast (B)	Change (B)-(A)
Revenue	591.0	420.0	-171.0
Operating Profit % vs Revenue	6.7 1.1%	-75.0 -17.9%	-81.7
Profit before income taxes % vs Revenue	11.8 2.0%	-70.0 -16.7%	-81.8
Profit attributable to owners of the parent % vs Revenue	7.6 1.3%	-50.0 -11.9%	-57.6
EPS	¥ 19.93	-¥136.19	-¥156.12
Annual Dividends	¥ 40	¥20	-¥20
FCF	-4.8	-	-
Exchange Rate:	¥ 109	¥106	Impact on revenue
US \$	+ 103	+100	Approx9.0
EURO	¥ 121	¥116	Impact on Operating Profit Approx2.0

Note: EPS (Basic Earnings per Share) = Profit attributable to owners of the parent / Average number of shares (The actual of FY2020/3 is calculated by approx. 0.386B shares. The forecast of FY2021/3 is calculated by approx. 0.367B, average number of shares from April to June 2020). FCF for FY2021/3 is undecided.

Forecast for the year ending March 31, 2021: Operating deficit breakdown





Note: -¥5.0B of restructuring relevant expenses was posted -¥0.3B in Q1. And it will be done -¥0.7B in Q2 and -¥4.0B in 2H. -¥20.0B of risk buffer will be posted in 2H.

Forecast for the year ending March 31, 2021: Financial Highlights by Segment



Billions of yen	_	FY2020/3 Actual (A)	FY2021/3 Forecast (B)	Change (B)-(A)
Tues wise a Due de ete	Revenue	225.8	130.0	-42.4%
Imaging Products Business	Operating	-17.1	-40.0	-¥22.9B
Business	Profit	(-14.4)	(-35.0)	
Dyspision Equipment	Revenue	245.0	175.0	-28.6%
Precision Equipment Business	Operating	48.0	10.0	-¥38.0B
Dusiness	Profit	(48.0)	(10.0)	
	Revenue	62.0	57.0	-8.1%
Healthcare Business	Operating	-2.4	-5.0	-¥2.6B
	Profit	(-2.4)	(-5.0)	
To describe Makes la ma	Revenue	58.0	58.0	±0%
Industrial Metrology and Others	Operating	1.8	0.0	-¥1.8B
and Others	Profit	(1.8)	(0.0)	
	Revenue	_	-	-
Corporate P/L non-attributable to any reportable segments	Operating	-23.6	-40.0	-¥16.4B
,	Profit	(-21.9)	(-40.0)	
	Revenue	591.0	420.0	-28.9%
Consolidated	Operating	6.7	-75.0	-¥81.7B
	Profit	(11.2)	(-70.0)	


Note: Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

Revenue of ¥5.3B and operating profit of ¥1.3B have been transferred from Industrial Metrology and Others to the Precision Equipment Business as a result of retroactive application to FY2020/3.

Corporate P/L not attributable to any reportable segments includes the elimination of intersegment transactions that amount to -\(\frac{4}{2}.1B\), the gain from unused land sales of \(\frac{4}{3}.8B\) in FY2020/3 and risk buffer of -\(\frac{4}{2}0.0B\) in FY2021/3. The Semiconductor Related Equipment Business, which had belonged to Industrial Metrology and Others, has been transferred to the Precision Equipment Business.

Forecast for the year ending March 31, 2021: Imaging Products Business





Revenue: Down ¥95.8B YoY


- In addition to the shrinking market, sales decreased significantly due to the impact of COVID-19. Although our business has been recovering since June, the impact of COVID-19 will remain throughout the fiscal year.
- Release new products consecutively in mid-range to high-end targeting professionals and hobbyists and continue to fill out the mirrorless lens lineup.

Operating profit: Down ¥22.9B YoY

- Proceeded reductions of business costs through restructuring. However, efforts could not offset the impact of COVID-19, leading to significant loss.
- Assuming the impact of COVID-19 will continue to next year and beyond. Therefore, the ¥50.0B business cost reduction in the Midterm management plan will be increased to ¥60.0B. Last year, more than ¥25.0B in business costs were cut. This year, the plan is to reduce approx. ¥15.0B.
- Last year, restructuring relevant expenses were ¥2.7B. This year, the plan is approx. ¥5.0B, primarily in the 2H.

Forecast for the year ending March 31, 2021: Precision Equipment Business





Revenue: Down ¥70.0B YoY


- FPD: Capex for small and mid-sized panels are recovering. Capex for large panels remains steady.
- FPD: Some of the installations halted since February have resumed in July, albeit with restrictions on the installation. The number of systems that can complete installation are limited this year. Those that are not completed will be booked as sales of next year.
- Semiconductor: Systems sales volumes dropped substantially due to delays of system delivery and orders for some customers by the impact of COVID-19, as well as our major customer is at their shifting point of investment.

Operating profit: Down ¥38.0B YoY

- The decline in profit will widen as the effect of declining revenue in FPD and Semiconductor couples with a substantial increase in R&D investment in growth areas.

Forecast for the year ending March 31, 2021: Healthcare Business





• Revenue: Down ¥5.0B YoY


- Revenue will decline year-on-year as the large impact of declining sales in the 1H outstrips the recovery in the 2H as order-taking resumed in both biological microscopes and retinal diagnostic imaging systems.
- The contract cell manufacturing business is moving forward as planned in terms of the facility extension and progress on projects with customers. Revenue increased compared to last year in regenerative medicine.

Operating profit: Down ¥2.6B YoY

- Loss grew due to shrinking revenue.
- Turn to profitability planned for next year, one year late to due the impact of COVID-19.

Forecast for the year ending March 31, 2021: Industrial Metrology Business and Others





• Revenue: No change YoY

- Industrial Metrology is expected to see a recovery in orders in the 2H. However, revenue will decrease substantially due to delays in recoveries of customer capex related to electronics components and automotive.
- Among Others, the Digital Solutions Business is growing its sales.

Operating profit: Down ¥1.8B YoY

- Industrial Metrology profit down due to declining revenue.



Reference Data

Forecast for the year ending March 31, 2021: Financial Highlights (Half year/Full year)



	FY2018/3	FY2019/3		FY2020/3		FY	2021/3 Foreca	ist
Billions of yen	Full year	Full year	1H	2H	Full year	1H	2H	Full year
Revenue	717.0	708.6	291.0	300.0	591.0	165.0	255.0	420.0
Operating Profit % vs Revenue	56.2 7.8%	82.6 11.7%	17.5 6.0%	-10.8 -3.6%	6.7 1.1%	-40.0 -24.2%	-35.0 -13.7%	-75.0 -17.9%
Profit before income taxes	56.2	87.9	20.1	-8.3	11.8	-35.0	-35.0	-70.0
% vs Revenue	7.8%	12.4%	6.9%	-2.8%	2.0%	-21.2%	-13.7%	-16.7%
Profit attributable to owners of the parent	34.7	66.5	16.3	-8.7	7.6	-25.0	-25.0	-50.0
% vs Revenue	4.8%	9.4%	5.6%	-2.9%	1.3%	-15.2%	-9.8%	-11.9%
EPS	¥87.76	¥167.86		¥19.93			-¥136.19	
Annual Dividends	¥36	¥60		¥40			¥20	
ROE	6.3%	11.2%		1.3%			-10.0%	
FCF	90.2	43.5		-4.8			-	
Exchange Rate: US\$ EURO	¥111 ¥130	¥111 ¥128	¥109 ¥121	¥109 ¥120	¥109 ¥121	¥106 ¥117	¥105 ¥115	¥106 ¥116

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B.

Forecast for the year ending March 31, 2021: Financial Highlights by Segment (Half year/Full year)



		FY2018/3	FY2019/3		FY2020/3		Fored	cast for FY20	21/3
Billions of yen	_	Full year	Full year	1H	2H	Full year	1H	2H	Full year
Torra mile or December at a	Revenue	360.7	296.1	119.0	106.8	225.8	55.0	75.0	130.0
Imaging Products Business	Operating	30.2	22.0	2.0	-19.1	-17.1	-20.0	-20.0	-40.0
	Profit	(36.0)	(22.6)	(2.2)	(-16.6)	(-14.4)	(-19.0)	(-16.0)	(-35.0)
Duncisian Fassianant	Revenue	226.3	274.5	117.6	127.4	245.0	65.0	110.0	175.0
Precision Equipment Business	Operating	53.3	81.7	26.0	22.0	48.0	-2.0	12.0	10.0
	Profit	(53.3)	(81.7)	(26.0)	(22.0)	(48.0)	(-2.0)	(12.0)	(10.0)
	Revenue	56.8	65.4	30.0	32.0	62.0	22.0	35.0	57.0
Healthcare Business	Operating	-3.2	-1.9	-1.2	-1.2	-2.4	-5.0	0.0	-5.0
	Profit	(-3.2)	(-1.9)	(-1.2)	(-1.2)	(-2.4)	(-5.0)	(0.0)	(-5.0)
To describe Maturale me	Revenue	73.2	72.5	24.2	33.8	58.0	23.0	35.0	58.0
Industrial Metrology and Others	Operating	5.0	6.9	1.8	0.0	1.8	-2.0	2.0	0.0
	Profit	(7.8)	(7.5)	(1.8)	(0.0)	(1.8)	(-2.0)	(2.0)	(0.0)
Corporate P/L non-	Revenue	_	_	_	_	_	_	_	-
attributable to any	Operating	-29.1	-26.1	-11.1	-12.5	-23.6	-11.0	-29.0	-40.0
reportable segments	Profit	(-29.1)	(-25.6)	(-9.4)	(-12.5)	(-21.9)	(-11.0)	(-29.0)	(-40.0)
	Revenue	717.0	708.6	291.0	300.0	591.0	165.0	255.0	420.0
Consolidated	Operating	56.2	82.6	17.5	-10.8	6.7	-40.0	-35.0	-75.0
	Profit	(64.9)	(84.4)	(19.4)	(-8.2)	(11.2)	(-39.0)	(-31.0)	(-70.0)

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B. Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

The Semiconductor Related Equipment Business, which had belonged to Industrial Metrology and Others, has been transferred to the Precision Equipment Business.

Revenue of ¥5.3B and operating profit of ¥1.3B have been transferred from Industrial Metrology and Others to the Precision Equipment Business as a result of retroactive application to FY2020/3.

1st quarter of the year ending March 31, 2021: Financial Highlights by Segment




		FY 2020/3			FY2021/3	
Billions of yen		Q1	Q2	Q3	Q4	Q1
	Revenue	67.3	51.7	70.0	36.8	25.1
Imaging Products Business	Operating	3.5	-1.5	-0.8	-18.3	-8.1
	Profit	(3.5)	(-1.3)	(-0.2)	(-16.4)	(-7.8)
Dun sinian Familian aut	Revenue	51.8	65.8	52.6	74.8	19.6
Precision Equipment Business	Operating	10.3	15.7	10.7	11.3	-5.1
	Profit	(103)	(15.7)	(10.7)	(11.3)	(-5.1)
	Revenue	12.9	17.1	16.5	15.5	10.3
Healthcare Business	Operating	-1.9	0.7	-0.4	-0.8	-2.4
	Profit	(-1.9)	(0.7)	(-0.4)	(-0.8)	(-2.4)
To describe Makes I am	Revenue	10.8	13.4	14.3	19.5	9.5
Industrial Metrology and Others	Operating	0.2	1.6	0.9	-0.9	-0.4
	Profit	(0.2)	(1.6)	(0.9)	(-0.9)	(-0.4)
	Revenue	_	_	_	_	-
Corporate P/L non-attributable to any reportable segments	Operating	-2.9	-8.2	-6.3	-6.2	-4.4
	Profit	(-2.9)	(-6.5)	(-6.3)	(-6.2)	(-4.4)
	Revenue	142.9	148.1	153.4	146.6	64.7
Consolidated	Operating	9.3	8.2	4.0	-14.8	-20.5
	Profit	(9.3)	(10.1)	(4.7)	(-12.9)	(-20.2)

Note: Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

1st quarter of the year ending March 31, 2021: Financial Position Breakdown







Capital Expenditures, Depreciation and Inventory



CAPITAL EXPENDITURES, DEPRECIATION



INVENTORY BREAKDOWN



Note: Capital expenditures in FY2020/3 includes the leased assets of approx. ¥4.0B upon the adoption of IFRS16. Forecast for FY2021/3 is closed its under examination basing FY2020/3.

Depreciation from FY2018/3 includes the amortization of capitalized R&D costs and in FY2020/3 depreciation of the leased asset includes approx. ¥7.0B, same as capital expenditures.


The Semiconductor Related Equipment Business, which had belonged to Industrial Metrology and Others, has been transferred to the Precision Equipment Business.

Inventory of ¥3.0B in the end of FY2019/6 and ¥2.6B in the end of FY2020/3 have been transferred from Industrial Metrology and Others to the Precision Equipment Business as a result of retroactive application to the end of FY2020/3 respectively.

1st quarter of the year ending March 31, 2021: Revenue Breakdown








BY REGION


Others

15%

9.6

Europe







R&D Expenditures



R&D EXPENDITURES




R&D EXPENDITURES BREAKDOWN



Note: R&D expenditures after FY2018/3 includes capitalization of some development expenditures. In FY2021/3, non-disclosure because of under scrutiny based on the same level as FY2020/3.

Cash Flow History






Note: FCF (free cash flows) = CF from operating activities + CF from investing activities; Japanese Standard is employed for FY2015/3 and prior, and IFRS is adopted for FY2016/3 and after. FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents

Imaging Products Business: Sales Units






DCIL(Digtal Camera-Interchangeable Lens Type)
 Interchangeable Lens
 CDSC(Compact Digital Still Camera)

Precision Equipment Business: Sales Units



FPD LITHOGRAPHY SYSTEMS SALES BY GENERATION


SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)



Note: The unit sales of new semiconductor lithography systems is 17 units in FY2018/3, 21 units in FY2019/3, 34 units in FY2020/3 and 19 units (forecast) in FY2021/3.


Precision Equipment Business: Sales Units





Precision Equipment Business: Sales Units





■ i-line ■ KrF ■ ArF ■ ArF immersion

18/3-Q118/3-Q218/3-Q318/3-Q419/3-Q119/3-Q219/3-Q319/3-Q420/3-Q120/3-Q220/3-Q320/3-Q421/3-Q1

Forecast for the year ending March 31, 2021: Foreign Exchange Impact



	Exchange Rate	Financial Impact from Fluctuation by 1 yen			
	FY2021/3 Forecast for Q2~Q4	Revenue Q2~Q4	Operating Profit Q2~Q4		
US \$	¥ 105	Approx. ¥ 1.5billion	Approx. ¥0.2billion		
EURO	¥115	Approx. ¥ 0.5billion	Approx. ¥0.2billion		

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US \$ and EURO.

Disclaimer Regarding Forecast and Projections



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

